Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basimglurant adjunctive therapy in MDD
NCT01437657Phase 2Completed
- Sponsor
- Roche
- Start
- Oct 2011
- Primary completion
- Sep 2013
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of basimglurant in major depressive disorder (MDD) (3 arms), sponsored by Roche. Primary endpoint: Montgomery Asberg Depression Rating Scale at 6 weeks. Started Oct 2011; status: completed.
02
Drugs
basimglurant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01437657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01437657.